SRC Family Kinase Inhibitor as a Potential Treatment for Fragile X Syndrome

Discover the Smith lab’s new approach to treating Fragile X syndrome using Saracatinib, originally a cancer drug. Learn how this $100,000 FRAXA research grant-funded study opens up hopeful avenues.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (47)